Lucid Diagnostics announces positive NCI study: EsoGuard detects 89% of short-segment precancers

Lucid Diagnostics Inc.

EsoGuard showed 89% sensitivity for short-segment Barrett's esophagus (SSBE) in NCI-sponsored multicenter study.
Detected 100% of cancers; overall sensitivity/specificity 85% each; estimated NPV 98% and PPV 39%.
Study published in American Journal of Gastroenterology; investigators from Mayo Clinic, Johns Hopkins, Cleveland Clinic.
Company plans to seek Medicare coverage via MolDX pre-submission meeting and formal technical assessment.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.